The category eye diseases as defined by the German Federal Joint Committee (G-BA) groups together medicinal products for the treatment of diseases such as macular degeneration, and for the reduction of intraocular pressure, postoperative pain after eye operations, inflammation after cataract operations or vitreomacular traction. So far XX different medicinal products have been assessed in XX procedures. A major additional benefit has been demonstrated for xx% of the subpopulations (weighted according to patient share in the resolution). A considerable additional benefit has been found for XX% of these subpopulations and a minor additional benefit for XX%. A non-quantifiable additional benefit has been demonstrated for XX% of the subpopulations.

By contrast, the G-BA has stated that an additional benefit compared to the appropriate comparative treatment has not been proved for XX% of the weighted subpopulations, corresponding to xx% of the theoretical total population of xx million patients for all medicinal products evaluated in this therapeutic area.